Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa.
cytokines
hepcidin
interleukin-22
hidradenitis suppurativa
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
22 Sep 2021
22 Sep 2021
Historique:
pubmed:
14
9
2021
medline:
25
9
2021
entrez:
13
9
2021
Statut:
epublish
Résumé
Current understanding of the underlying pathophysiology of hidradenitis suppurativa (HS) links the disease with proinflammatory activation and autoimmune processes. This study investigated serum levels of interleukin (IL)-22, a cytokine critically involved in epithelial homeostasis, in the context of the broad clinical spectrum of patients with HS. The study also assessed the relationship between serum IL-22 and pro-inflammatory activation (as evidenced by serum level of IL-6) and serum hepcidin (central regulator of systemic iron homeostasis). Serum concentrations of IL-22 were assessed in 74 patients with HS and 15 healthy subjects. Compared with healthy controls, patients with HS demonstrated decreased levels of serum IL-22 (median; interquartile range (IQR): 12.4 pg/ml (9.8; 23.5) vs 34.8 pg/ml (24.8; 39.8), p < 0.001 vs controls). Disease severity (assessed both with Hurley staging and Hidradenitis Suppurativa Severity Index) did not differentiate IL-22 levels (p > 0.1 in both comparisons). Serum levels of IL-22 and IL-6 did not correlate with each other (R=-0.17, p = ns). In a subgroup of 24 patients with HS with pro-inflammatory activation, the mean level of IL-22 was similar to that of the remaining patients (median (IQR): 9.8 pg/ml (8.5; 15.0) vs 12.0 pg/ml (9.4; 16.3), p = ns). Patients with HS demonstrated a decreased level of hepcidin (mean: 31.3 ± 25.9 pg/ml), which correlated with the levels of IL-22 (R=0.36, p <0.05). Patients with HS demonstrated significantly decreased levels of serum IL-22, which was neither correlated with pro-inflammatory status nor associated with disease severity, but correlated modestly with serum hepcidin.
Identifiants
pubmed: 34515804
doi: 10.2340/00015555-3928
pmc: PMC9425619
doi:
Substances chimiques
Cytokines
0
Hepcidins
0
Interleukins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00558Références
Nat Rev Drug Discov. 2014 Jan;13(1):21-38
pubmed: 24378801
Immunol Invest. 2018 Jan;47(1):57-70
pubmed: 28972431
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
J Am Acad Dermatol. 2010 Feb;62(2):205-17
pubmed: 20115947
Ann Dermatol. 2012 Nov;24(4):393-7
pubmed: 23197903
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S8-11
pubmed: 26470623
J Immunol. 2013 Aug 15;191(4):1845-55
pubmed: 23836059
Dermatol Ther. 2020 Nov;33(6):e13845
pubmed: 32544258
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Br J Dermatol. 2009 Oct;161(4):831-9
pubmed: 19438453
Acta Derm Venereol. 2009 Nov;89(6):601-3
pubmed: 19997690
Eur Heart J. 2013 Mar;34(11):827-34
pubmed: 23178646
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
Int J Dermatol. 2014 Oct;53(10):1186-96
pubmed: 24961484
J Invest Dermatol. 2016 Sep;136(9):1768-1780
pubmed: 27206704
JAMA. 2017 Nov 28;318(20):2019-2032
pubmed: 29183082
Autoimmun Rev. 2017 Dec;16(12):1209-1218
pubmed: 29037907
JAMA Dermatol. 2016 Jan;152(1):52-59
pubmed: 26579854
J Mol Med (Berl). 2009 May;87(5):523-36
pubmed: 19330474
J Biol Chem. 2015 Jul 31;290(31):18975-83
pubmed: 26055723
Dermatology. 2020;236(1):52-58
pubmed: 31927542
Int J Clin Exp Pathol. 2014 Jan 15;7(2):474-80
pubmed: 24551268
Immunotherapy. 2019 Jan;11(1):45-59
pubmed: 30702012
Dermatol Clin. 2016 Jan;34(1):51-8
pubmed: 26617358
J Immunol. 2011 Jan 15;186(2):1228-39
pubmed: 21148041